T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.

@article{Pricl2005T315ImutatedBI,
  title={T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.},
  author={Sabrina Pricl and Maurizio Fermeglia and Marco Ferrone and Elena Tamborini},
  journal={Molecular cancer therapeutics},
  year={2005},
  volume={4 8},
  pages={
          1167-74
        }
}
The early stage of chronic myeloid leukemia is triggered by the tyrosine kinase Bcr-Abl. Imatinib mesylate, a selective inhibitor of Bcr-Abl, has been successful in chronic myeloid leukemia clinical trials, but short-lived remissions are usually observed in blast crisis patients. Sequencing of the BCR-ABL gene in relapsed patients revealed a set of mutants that mediate drug resistance. Previously reported work postulated that the missense T315I mutation both alters the three-dimensional… CONTINUE READING
Highly Cited
This paper has 62 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

62 Citations

0510'08'11'14'17
Citations per Year
Semantic Scholar estimates that this publication has 62 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Antechamber, an accessory software package for molecular mechanical calculations

J Wang, W Wang, PA Kollman, DA. Case
J Comput Chem • 2005
View 1 Excerpt

Imatinib mesylate--a new oral targeted therapy.

The New England journal of medicine • 2002
View 1 Excerpt